LT2435024T - Kompozicijos aktyvių agentų pristatymui į kvėpavimo takus ir susiję būdai bei sistemos - Google Patents

Kompozicijos aktyvių agentų pristatymui į kvėpavimo takus ir susiję būdai bei sistemos

Info

Publication number
LT2435024T
LT2435024T LTEP10727551.3T LT10727551T LT2435024T LT 2435024 T LT2435024 T LT 2435024T LT 10727551 T LT10727551 T LT 10727551T LT 2435024 T LT2435024 T LT 2435024T
Authority
LT
Lithuania
Prior art keywords
compositions
systems
active agents
associated methods
respiratory delivery
Prior art date
Application number
LTEP10727551.3T
Other languages
English (en)
Inventor
Reinhard Vehring
Michael Steven Hartman
Adrian Edward Smith
Vidya B. Joshi
Sarvajna Kumar Dwivedi
Original Assignee
Pearl Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pearl Therapeutics, Inc. filed Critical Pearl Therapeutics, Inc.
Publication of LT2435024T publication Critical patent/LT2435024T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1025—Respiratory system
LTEP10727551.3T 2009-05-29 2010-05-28 Kompozicijos aktyvių agentų pristatymui į kvėpavimo takus ir susiję būdai bei sistemos LT2435024T (lt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18256509P 2009-05-29 2009-05-29
US25817209P 2009-11-04 2009-11-04
US30936510P 2010-03-01 2010-03-01
US34553610P 2010-05-17 2010-05-17
PCT/US2010/036650 WO2010138862A2 (en) 2009-05-29 2010-05-28 Compositions for respiratory delivery of active agents and associated methods and systems

Publications (1)

Publication Number Publication Date
LT2435024T true LT2435024T (lt) 2016-09-26

Family

ID=42269864

Family Applications (8)

Application Number Title Priority Date Filing Date
LTEP10727553.9T LT2435025T (lt) 2009-05-29 2010-05-28 Veikliosios medžiagos tiekimas per kvėpavimo takus
LTEP10727551.3T LT2435024T (lt) 2009-05-29 2010-05-28 Kompozicijos aktyvių agentų pristatymui į kvėpavimo takus ir susiję būdai bei sistemos
LTEP16164849.8T LT3111927T (lt) 2009-05-29 2010-05-28 Kompozicijos veikliųjų agentų respiraciniam peteikimui ir susiję būdai ir sistemos
LTEP16164845.6T LT3106149T (lt) 2009-05-29 2010-05-28 Kompozicijos, skirtos ilgo poveikio muskarino antagonistų ir ilgo poveikio beta 2 adrenerginio receptorius agonistų pateikimui į plaučius, ir susiję būdai ir sistemos
LTEP16164844.9T LT3111926T (lt) 2009-05-29 2010-05-28 Kompozicijos, būdai ir sistemos dviejų arba kelių veikliųjų agentų respiraciniam pateikimui
LTEP10721258.1T LT2435023T (lt) 2009-05-29 2010-05-28 Kompozicijos, skirtos ilgai veikiančių muskarininių antagonistų ir ilgai veikiančių beta-2-adrenerginio receptoriaus agonistų pristatymui į plaučius, ir susiję būdai bei sistemos
LTPA2019014C LTC2435025I2 (lt) 2009-05-29 2019-06-17 Veikliosios medžiagos tiekimas per kvėpavimo takus
LTPA2021511C LTC2435024I2 (lt) 2009-05-29 2021-06-04

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP10727553.9T LT2435025T (lt) 2009-05-29 2010-05-28 Veikliosios medžiagos tiekimas per kvėpavimo takus

Family Applications After (6)

Application Number Title Priority Date Filing Date
LTEP16164849.8T LT3111927T (lt) 2009-05-29 2010-05-28 Kompozicijos veikliųjų agentų respiraciniam peteikimui ir susiję būdai ir sistemos
LTEP16164845.6T LT3106149T (lt) 2009-05-29 2010-05-28 Kompozicijos, skirtos ilgo poveikio muskarino antagonistų ir ilgo poveikio beta 2 adrenerginio receptorius agonistų pateikimui į plaučius, ir susiję būdai ir sistemos
LTEP16164844.9T LT3111926T (lt) 2009-05-29 2010-05-28 Kompozicijos, būdai ir sistemos dviejų arba kelių veikliųjų agentų respiraciniam pateikimui
LTEP10721258.1T LT2435023T (lt) 2009-05-29 2010-05-28 Kompozicijos, skirtos ilgai veikiančių muskarininių antagonistų ir ilgai veikiančių beta-2-adrenerginio receptoriaus agonistų pristatymui į plaučius, ir susiję būdai bei sistemos
LTPA2019014C LTC2435025I2 (lt) 2009-05-29 2019-06-17 Veikliosios medžiagos tiekimas per kvėpavimo takus
LTPA2021511C LTC2435024I2 (lt) 2009-05-29 2021-06-04

Country Status (31)

Country Link
US (11) US20110132357A1 (lt)
EP (6) EP3111927B1 (lt)
JP (10) JP5873013B2 (lt)
KR (7) KR101976107B1 (lt)
CN (6) CN102458364B (lt)
AR (3) AR076621A1 (lt)
AU (3) AU2010253950C1 (lt)
BR (3) BRPI1011508A2 (lt)
CA (3) CA2763936C (lt)
CY (7) CY1118040T1 (lt)
DK (6) DK2435024T3 (lt)
ES (6) ES2593429T3 (lt)
HK (6) HK1169026A1 (lt)
HR (6) HRP20161102T1 (lt)
HU (8) HUE029532T2 (lt)
IL (3) IL216468B (lt)
LT (8) LT2435025T (lt)
LU (2) LUC00124I2 (lt)
ME (1) ME03631B (lt)
MX (4) MX337126B (lt)
NL (1) NL300995I2 (lt)
NO (2) NO2019026I1 (lt)
PH (1) PH12017500778A1 (lt)
PL (6) PL2435025T3 (lt)
PT (6) PT2435024T (lt)
RU (5) RU2016117972A (lt)
SI (6) SI2435024T1 (lt)
SM (3) SMT201600327B (lt)
TW (9) TWI717511B (lt)
WO (3) WO2010138868A2 (lt)
ZA (4) ZA201108275B (lt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003220125B2 (en) 2002-03-20 2006-06-15 Mannkind Corporation Inhalation apparatus
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
EP2322180B1 (en) 2004-08-23 2015-05-27 MannKind Corporation Diketopiperazine salts for drug delivery
US10002325B2 (en) 2005-03-30 2018-06-19 Primal Fusion Inc. Knowledge representation systems and methods incorporating inference rules
RU2390325C2 (ru) 2005-09-14 2010-05-27 Маннкайнд Корпорейшн Способ приготовления лекарственного препарата, основанный на увеличении сродства активных агентов к поверхностям кристаллических микрочастиц
RU2403059C2 (ru) 2006-02-22 2010-11-10 Маннкайнд Корпорейшн Способ улучшения фармацевтических свойств микрочастиц, содержащих дикетопиперазин и активный агент
US8636001B2 (en) 2008-06-13 2014-01-28 Mannkind Corporation Dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
DK2609954T3 (da) 2008-06-20 2022-02-14 Mannkind Corp Interaktivt apparat til realtidsafbildning af inhalationspræstationer
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
KR101976107B1 (ko) * 2009-05-29 2019-05-09 펄 테라퓨틱스 인코포레이티드 활성제의 호흡기 전달
EP2582421A1 (en) * 2010-06-21 2013-04-24 MannKind Corporation Dry powder drug delivery system and methods
US10474647B2 (en) 2010-06-22 2019-11-12 Primal Fusion Inc. Methods and devices for customizing knowledge representation systems
WO2012135765A2 (en) 2011-04-01 2012-10-04 Mannkind Corporation Blister package for pharmaceutical cartridges
CN105106200A (zh) * 2011-05-17 2015-12-02 珍珠治疗公司 用于呼吸递送两种或多种活性剂的组合物、方法和系统
CN103687483A (zh) * 2011-05-17 2014-03-26 珍珠治疗公司 用于呼吸递送两种或多种活性剂的组合物、方法和系统
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
WO2013153146A1 (en) * 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
CN102872027B (zh) * 2012-09-18 2014-03-12 刘晓忠 一种治疗肺部疾病的药物颗粒的制备和吸入式复方气雾剂的制备
WO2014115127A1 (en) * 2013-01-28 2014-07-31 Incozen Therapeutics Pvt. Ltd. Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
US9682038B2 (en) 2013-01-31 2017-06-20 Prosonix Limited Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy
GB201301721D0 (en) * 2013-01-31 2013-03-20 Prosonix Ltd Pharmaceutical Preparations
CA2901015A1 (en) * 2013-03-04 2014-09-12 Besins Healthcare Luxembourg Sarl Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles
EP2968110A1 (en) * 2013-03-14 2016-01-20 Novartis AG Deamorphization of spray-dried formulations via spray-blending
SG11201507286QA (en) * 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
JP6473738B2 (ja) 2013-04-01 2019-02-20 パルマトリックス，インコーポレイテッド チオトロピウム乾燥粉末
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
RU2015154720A (ru) * 2013-05-22 2017-06-27 Перл Терапьютикс, Инк. Композиции, способы и системы для респираторной доставки трех или более активных средств
MX2020009878A (es) 2013-07-18 2022-07-27 Mannkind Corp Composiciones farmaceuticas en polvo seco estables al calor y metodos.
PT3054920T (pt) * 2013-10-07 2021-03-23 Teva Branded Pharmaceutical Products R&D Inc Inalador de pó seco
AU2014352793B2 (en) * 2013-11-22 2019-05-09 Teva Branded Pharmaceutical Products R&D, Inc. An inhalable medicament
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
CN104188941B (zh) * 2014-09-02 2016-11-16 重庆和平制药有限公司 一种制备盐酸克仑特罗吸入粉雾剂的方法
KR20170057451A (ko) * 2014-10-01 2017-05-24 에이엘에스 마운틴 엘엘씨 비이온성 계면 활성제와 함께 아스피린, 메트포르민 및 세로토닌을 포함하는 약학 조성물
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
WO2016170518A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
TW201735914A (zh) 2015-12-22 2017-10-16 阿斯特捷利康公司 用於治療慢性阻塞性肺疾病之醫藥組成物
WO2017157265A1 (zh) * 2016-03-15 2017-09-21 广东东阳光药业有限公司 喷雾剂、喷雾装置以及喷雾组件
US20190269703A1 (en) * 2016-05-17 2019-09-05 Mayo Foundation For Medical Education And Research Materials and methods for treating chronic cough
CN109310623B (zh) 2016-06-30 2022-10-21 菲利普莫里斯生产公司 尼古丁颗粒
ES2892673T3 (es) 2016-09-19 2022-02-04 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende glicopirrolato
JP6906947B2 (ja) * 2016-12-22 2021-07-21 キヤノン株式会社 画像処理装置、撮像装置、画像処理方法およびコンピュータのプログラム
CN106943350A (zh) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法
CN107243080B (zh) * 2017-06-21 2021-11-12 上海上药信谊药厂有限公司 一种吸入式气雾剂、其原料组合物及制备方法
BR112020006696A2 (pt) * 2017-10-09 2020-10-06 Pearl Therapeutics, Inc. sistemas de aplicação de fármacos e métodos relativos
JP7372727B2 (ja) 2017-11-20 2023-11-01 三菱重工業株式会社 系統運用者側コンピュータ、発電事業者側コンピュータ、電力システム、制御方法及びプログラム
EP3861988A4 (en) * 2018-10-02 2022-06-29 Meijo University Educational Foundation Powder inhaler, method for assessing same, and use of same
CN109632555B (zh) * 2018-12-28 2021-07-27 上海新黄河制药有限公司 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法
WO2020229966A1 (en) * 2019-05-10 2020-11-19 Glenmark Pharmaceutical Limited Stable aerosol composition for inhalation comprising glycopyrronium
CN112137957B (zh) 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
US20200405700A1 (en) * 2019-06-27 2020-12-31 Cai Gu Huang Inhalable formulation of a solution containing formoterol fumarate and aclidinium bromide
CN112972384B (zh) * 2019-12-02 2022-03-18 长风药业股份有限公司 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
CA3165307A1 (en) * 2020-02-20 2021-08-26 Enrico Zambelli Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
BR112022023307A2 (pt) * 2020-05-18 2022-12-20 Orexo Ab Composição farmacêutica para entrega de fármacos
US20220000767A1 (en) * 2020-07-06 2022-01-06 Sensory Cloud, Inc. Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery of same to the nose, trachea and main bronchi
WO2022016068A1 (en) * 2020-07-16 2022-01-20 Tbd Pharma Llc Dexamethasone solution for the treatment of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infections
WO2022148418A1 (zh) * 2021-01-08 2022-07-14 江苏恒瑞医药股份有限公司 可通过定量吸入器递送的药物组合物
JP2024049405A (ja) * 2021-02-22 2024-04-10 興和株式会社 新規吸入剤
TW202317079A (zh) 2021-07-09 2023-05-01 美商阿斯特捷利康有限責任公司 用於氣溶膠遞送之組合物、方法及系統
WO2023094826A1 (en) 2021-11-25 2023-06-01 Orexo Ab Pharmaceutical composition comprising adrenaline
WO2023119093A1 (en) 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery
WO2023212191A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Combination of albuterol and budesonide for the treatment of asthma

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (lt) 1972-05-19 1975-08-18 Bofors Ab
US4187301A (en) * 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
US4335121A (en) * 1980-02-15 1982-06-15 Glaxo Group Limited Androstane carbothioates
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GB8432063D0 (en) 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
ATE92762T1 (de) 1989-09-08 1993-08-15 Glaxo Group Ltd Medikamente.
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
IE912999A1 (en) 1990-09-07 1992-03-11 Abbott Lab Phenanthridine compounds
PL165803B1 (pl) 1990-09-10 1995-02-28 Schering Corp Sposób wytwarzania nowego monohydratu 9a, 21-dichloro-16-a metylo-1,4-pregnadieno-11 ß , 17a-diolo-3,20-diono-17-(2’furanokarboksylanu) PL PL PL PL
DE4108393A1 (de) 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
US5635563A (en) 1991-04-01 1997-06-03 Tomoegawa Paper Co., Ltd. Polyaniline derivatives and their production process
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
HU0004452D0 (lt) 1991-12-18 2001-01-29 Astra Ab
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5849263A (en) 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
ES2193186T3 (es) 1993-12-02 2003-11-01 Abbott Lab Composiciones medicamentosas en aerosol para la utilizacion con gases propulsores sin cfc.
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
DE69502179D1 (de) 1994-02-09 1998-05-28 Kinerton Ltd Verfahren zur trocknung eines materials aus einer lösung
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US6932962B1 (en) * 1994-12-22 2005-08-23 Astrazeneca Ab Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
US6309671B1 (en) * 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
CA2218074C (en) * 1995-04-14 2002-10-08 Mohammed Eljamal Powdered pharmaceutical formulations having improved dispersibility
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
DE19614421C2 (de) 1996-04-12 1999-12-16 Biovision Gmbh Verfahren zur Herstellung eines biodegradierbaren Knochenersatz- und Implantatwerkstoffes und biodegradierbarer Knochenersatz- und Implantatwerkstoff
GB9610821D0 (en) 1996-05-23 1996-07-31 Glaxo Wellcome Inc Metering apparatus
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US5886200A (en) * 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
ES2407135T3 (es) * 1996-11-11 2013-06-11 Meda Pharma Gmbh & Co. Kg Uso de (3S,2'R)-glicopirronio como medicamento
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
DE69840277D1 (de) 1997-03-20 2009-01-08 Schering Corp Dosierungsform eines Pulveragglomerates
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US6010935A (en) * 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
ATE248583T1 (de) * 1997-09-29 2003-09-15 Nektar Therapeutics In dosierinhalatoren verwendbare, stabilisierte zubereitungen
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
JP4422894B2 (ja) 1998-03-05 2010-02-24 千寿製薬株式会社 眼底組織細胞障害による疾患の予防および治療用医薬組成物
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US6260549B1 (en) * 1998-06-18 2001-07-17 Clavius Devices, Inc. Breath-activated metered-dose inhaler
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
ATE283033T1 (de) 1998-07-24 2004-12-15 Jago Res Ag Medizinische aerosolformulierungen
CA2338680C (en) * 1998-08-04 2008-10-14 Jago Research Ag Medicinal aerosol formulations
RU2221552C2 (ru) * 1998-11-13 2004-01-20 Джаго Рисерч Аг Сухой порошок для ингаляции
GB9912639D0 (en) * 1999-05-28 1999-07-28 Britannia Pharmaceuticals Ltd Improvements in and relating to treatment of respiratory conditions
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
EP2191718A1 (en) 1998-12-22 2010-06-02 The University of North Carolina at Chapel Hill Compounds and uses for the treatment of airway diseases and for the delivery of airway drugs
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
EP1158958B1 (en) 1999-03-05 2007-06-06 CHIESI FARMACEUTICI S.p.A. Improved powdery pharmaceutical compositions for inhalation
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
ES2193069T3 (es) 1999-04-14 2003-11-01 Glaxo Group Ltd Formulacion farmaceutica en aerosol.
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
AU780327B2 (en) 1999-06-30 2005-03-17 Novartis Ag Spray drying process for preparing dry powders
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
NZ500555A (en) * 1999-08-02 2000-11-24 Hovione Int Ltd Process for the preparation of mometasone furoate
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
MXPA02004193A (es) * 1999-10-29 2002-12-13 Inhale Therapeutic Syst Composiciones de polvo seco que tienen caracteristicas de dispersion mejoradas.
DE19961300A1 (de) * 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
JP2003531123A (ja) 2000-04-13 2003-10-21 イノバータ・バイオミッド・リミテッド 医薬品
ES2525087T5 (es) 2000-05-10 2018-06-28 Novartis Ag Polvos basados en fosfolípidos para administración de fármacos
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
WO2002014293A1 (en) 2000-08-15 2002-02-21 Carsten Berg Quaternary ammonium salts of 1,2-benzisothiazolin-3-one. preparation and use as biocides
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
US20040081627A1 (en) * 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
EP2283818B1 (en) 2000-11-30 2017-08-02 Vectura Limited Method of making particles for use in a pharmaceutical composition
EP1337240B2 (en) * 2000-11-30 2014-09-24 Vectura Limited Method of making particles for use in a pharmaceutical composition
GB0029562D0 (en) 2000-12-04 2001-01-17 Novartis Ag Organic compounds
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
AU2002230993B2 (en) 2000-12-29 2006-02-02 Alkermes, Inc. Particles for inhalation having sustained release properties
ITMI20010428A1 (it) * 2001-03-02 2002-09-02 Chemo Breath S A Composizioni ad uso inalatorio a base di formoterolo
IL157580A0 (en) * 2001-03-20 2004-03-28 Glaxo Group Ltd Inhalation drug combination
US20050074742A1 (en) * 2001-03-30 2005-04-07 Alain Domard Cartilaginous neo-tissue capable of being grafted
HU229798B1 (en) * 2001-03-30 2014-07-28 Jagotec Ag Medical aerosol compositions and process for their preparation
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
DE10202940A1 (de) * 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
DE10214264A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen eines Anhydrats
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
DE10216429A1 (de) 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
CN101700247A (zh) * 2002-06-12 2010-05-05 埃匹吉尼斯医药有限公司 利用脱氢表雄酮甾体及抗毒蕈碱药物治疗呼吸道疾病及肺病的组合物、制剂和试剂盒
DE10237739A1 (de) 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
US7244742B2 (en) * 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
ES2388537T3 (es) 2002-08-23 2012-10-16 Merck Sharp & Dohme Corp. Inhalador dosificador que contiene una formulación en suspensión de aerosol
CA2500065A1 (en) 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
ATE443005T1 (de) * 2002-10-15 2009-10-15 Cryovac Inc Verfahren zum auslösen, lagern und abgeben eines sauerstoffaufnehmers sowie gelagerter sauerstoffaufnehmer
EP1452179A1 (en) 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
DE10323966A1 (de) 2003-05-27 2004-12-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
EP1635786A2 (en) 2003-05-28 2006-03-22 Nektar Therapeutics Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agent microparticle with a partial or complete amino acid and/or phospholipid coat
EP1638567B1 (en) 2003-06-16 2012-02-29 Nycomed GmbH Composition comprising a pulmonary surfactant and sildenafil for the treatment of lung diseases
SE527190C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
JP2007500146A (ja) 2003-07-28 2007-01-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベータ受容体刺激薬及び抗コリン作用薬を含有する吸入用医薬品
KR20060052911A (ko) 2003-07-29 2006-05-19 베링거 인겔하임 인터내셔날 게엠베하 베타흥분제와 항콜린제를 포함하는 흡입용 의약품
KR20060052912A (ko) 2003-07-29 2006-05-19 베링거 인겔하임 인터내셔날 게엠베하 항콜린제와 스테로이드의 배합물 및 흡입으로 호흡기장애를 치료하기 위한 이의 용도
JP2007500676A (ja) 2003-07-31 2007-01-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とベータ受容体刺激薬を含む吸入用薬剤
EP1925293A3 (en) 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
US9308199B2 (en) 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
DE602004021959D1 (de) * 2003-11-21 2009-08-20 Theravance Inc Verbindungen mit agonistischer wirkung am beta2-adrenergen rezeptor und am muscarinischen rezeptor
SE0303270L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
AU2004312095A1 (en) * 2003-12-31 2005-07-21 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
PL1718336T3 (pl) * 2004-02-06 2008-11-28 Meda Pharma Gmbh & Co Kg Nowe połączenie środków antycholinergicznych i beta-mimetyków do leczenia chorób układu oddechowego
SI1713473T1 (sl) 2004-02-06 2013-06-28 Meda Pharma Gmbh & Co. Kg Kombinacija antiholinergikov in glukokortikoidov za dolgotranjno zdravljenje astme in KOPB
US20050287077A1 (en) * 2004-02-10 2005-12-29 James E. Shipley Process for preparing stable SOL of pharmaceutical ingredients and hydrofluorocarbon
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
KR20070026604A (ko) * 2004-06-18 2007-03-08 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 기관지 감염의 치료 방법
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
US20060140873A1 (en) 2004-12-27 2006-06-29 Chang Heng W Aerosol pharmaceutical compositions
JP2008534480A (ja) 2005-03-24 2008-08-28 ソーセイ アールアンドディ リミテッド グリコピロニウム塩およびそれらの治療的使用
MX2007012084A (es) * 2005-03-30 2007-11-21 Schering Corp Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada.
EP1879571A1 (de) 2005-04-23 2008-01-23 Boehringer Ingelheim International GmbH Arzneimittelkombination für die inhalation enthaltend neben einem anticholinergikum ein betamimetikum und ein steroid
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
WO2006128847A2 (en) 2005-05-31 2006-12-07 Boehringer Ingelheim International Gmbh Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor
CA2611907A1 (en) 2005-06-17 2006-12-21 Boehringer Ingelheim International Gmbh Mrp iv inhibitors for the treatment of respiratory diseases
AU2006272438B2 (en) 2005-07-15 2011-08-04 Map Pharmaceuticals, Inc. Method of particle formation
US20100183725A1 (en) 2005-07-15 2010-07-22 Map Pharmaceuticals, Inc. Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
CN100560598C (zh) * 2005-07-26 2009-11-18 上海奥锐特国际贸易有限公司 氟替卡松丙酸酯的合成方法
AT502396B1 (de) 2005-09-01 2007-03-15 Montanuniv Leoben Verfahren zum abtrennen von verunreinigungen aus einsatzstoffen
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
CN101321539B (zh) 2005-12-21 2010-09-29 Meda制药有限及两合公司 用于治疗炎性疾病的抗胆碱能药、糖皮质激素、β2-激动剂、PDE4抑制剂和抗白细胞三烯药的组合
US8263645B2 (en) * 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
WO2007095041A2 (en) 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
CA2653105A1 (en) 2006-05-24 2007-11-29 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0614621D0 (en) * 2006-07-24 2006-08-30 3M Innovative Properties Co Metered dose dispensers
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
PE20081788A1 (es) * 2007-02-19 2008-12-18 Cipla Ltd Combinaciones farmaceuticas
EP1964564A1 (en) * 2007-04-19 2008-09-03 LAB International SRL Breakthrough Pain Management
EP2036572A1 (en) 2007-09-04 2009-03-18 Novo Nordisk A/S Process for drying a protein, a protein particle and a pharmaceutical composition comprising the protein particle
CN101317821B (zh) * 2007-11-15 2012-01-04 陈晓东 适用于肺部给药的超细干粉颗粒及其制备方法
RU2482838C2 (ru) * 2007-12-13 2013-05-27 Новартис Аг Органические соединения
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
FR2940162B1 (fr) 2008-12-22 2011-02-25 Boehm & Cie Ets Outil de frappe multi-usages a mecanisme absorbant l'energie transmise au moyen de prehension
WO2010097188A1 (en) 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
KR101976107B1 (ko) * 2009-05-29 2019-05-09 펄 테라퓨틱스 인코포레이티드 활성제의 호흡기 전달
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CA2794941C (en) 2010-04-01 2018-05-15 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
EP2627317A4 (en) 2010-10-15 2014-08-20 Glaxo Group Ltd MEDICINAL FORMULATIONS FROM AGGREGATED NANOPARTICLES AND THEIR PREPARATION AND USE
CN103501776A (zh) 2011-02-17 2014-01-08 西普拉有限公司 甘罗铵与β2激动剂的组合物
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
CN103687483A (zh) 2011-05-17 2014-03-26 珍珠治疗公司 用于呼吸递送两种或多种活性剂的组合物、方法和系统
RU2015154720A (ru) 2013-05-22 2017-06-27 Перл Терапьютикс, Инк. Композиции, способы и системы для респираторной доставки трех или более активных средств

Also Published As

Publication number Publication date
CN107412212B (zh) 2021-01-22
ES2774391T3 (es) 2020-07-20
RU2016107464A3 (lt) 2019-08-19
KR20190049943A (ko) 2019-05-09
JP2018048150A (ja) 2018-03-29
US8808713B2 (en) 2014-08-19
SI2435025T1 (sl) 2016-10-28
HRP20200166T1 (hr) 2020-05-15
EP2435023B1 (en) 2016-07-06
CY1118034T1 (el) 2017-05-17
TW201109049A (en) 2011-03-16
HUE047823T2 (hu) 2020-05-28
PT2435024T (pt) 2016-10-13
LT3106149T (lt) 2020-03-10
CY2019031I2 (el) 2019-11-27
WO2010138884A2 (en) 2010-12-02
CN107669664A (zh) 2018-02-09
JP2016041713A (ja) 2016-03-31
US20110135737A1 (en) 2011-06-09
SI2435024T1 (sl) 2016-10-28
ES2774367T3 (es) 2020-07-20
WO2010138868A3 (en) 2011-04-28
JP2012528792A (ja) 2012-11-15
JP6169639B2 (ja) 2017-07-26
SMT201600329B (it) 2016-11-10
JP2015187108A (ja) 2015-10-29
CN102458364B (zh) 2016-11-02
BRPI1011220A2 (pt) 2016-03-15
ZA201208100B (en) 2013-07-31
RU2016107464A (ru) 2018-11-22
WO2010138862A2 (en) 2010-12-02
HRP20161102T1 (hr) 2016-11-04
US20150017247A1 (en) 2015-01-15
NL300995I1 (lt) 2019-06-24
AU2010253950A1 (en) 2011-12-08
CN102596176B (zh) 2017-09-19
TWI695723B (zh) 2020-06-11
SMT201600327B (it) 2016-11-10
CA2763941A1 (en) 2010-12-02
HUE031283T2 (hu) 2017-07-28
JP2012528199A (ja) 2012-11-12
CA2763936A1 (en) 2010-12-02
HK1218867A1 (zh) 2017-03-17
TW201642836A (zh) 2016-12-16
KR101926060B1 (ko) 2018-12-06
DK2435023T3 (en) 2016-10-24
AU2010253776A1 (en) 2011-11-24
AU2010253770B2 (en) 2014-12-11
EP2435024A2 (en) 2012-04-04
AU2010253950B2 (en) 2014-12-04
LUC00124I2 (lt) 2019-12-27
BRPI1011508A2 (pt) 2016-03-22
EP3111926A1 (en) 2017-01-04
EP3111927A1 (en) 2017-01-04
ZA201208101B (en) 2013-07-31
CY1118040T1 (el) 2017-05-17
CY2019031I1 (el) 2019-11-27
KR101748892B1 (ko) 2017-06-19
RU2020102859A (ru) 2021-07-26
US20190038548A1 (en) 2019-02-07
MX337126B (es) 2016-02-12
MX2020004077A (es) 2020-07-29
CY1122749T1 (el) 2021-03-12
PL3106149T3 (pl) 2020-06-01
HK1169026A1 (zh) 2013-01-18
RU2011154148A (ru) 2013-07-10
TWI633898B (zh) 2018-09-01
LUC00208I2 (lt) 2022-10-07
KR20120034631A (ko) 2012-04-12
LTC2435025I2 (lt) 2021-02-10
JP5873012B2 (ja) 2016-03-01
ZA201208102B (en) 2013-09-25
JP2017222706A (ja) 2017-12-21
CA2763936C (en) 2017-10-03
LT2435023T (lt) 2016-09-26
PT2435023T (pt) 2016-10-14
RU2015151358A (ru) 2019-01-16
SMT201600326B (it) 2016-11-10
US20110132356A1 (en) 2011-06-09
ES2593429T3 (es) 2016-12-09
SI3111927T1 (sl) 2020-08-31
JP2015199735A (ja) 2015-11-12
JP2018008942A (ja) 2018-01-18
PT3111926T (pt) 2020-02-28
RU2580315C2 (ru) 2016-04-10
AR076806A1 (es) 2011-07-06
SI2435023T1 (sl) 2016-10-28
ES2772253T3 (es) 2020-07-07
NL300995I2 (nl) 2019-10-29
CN105193773A (zh) 2015-12-30
AU2010253770A1 (en) 2011-11-24
US20170071850A1 (en) 2017-03-16
IL216466B (en) 2018-08-30
NO2019026I1 (no) 2019-06-13
AR076807A1 (es) 2011-07-06
HUS1900031I1 (hu) 2019-07-29
JP6348645B2 (ja) 2018-06-27
TW201919730A (zh) 2019-06-01
US20110132357A1 (en) 2011-06-09
AR076621A1 (es) 2011-06-22
PL3111927T3 (pl) 2020-06-29
HK1169027A1 (zh) 2013-01-18
TW201109051A (en) 2011-03-16
BRPI1011229B1 (pt) 2020-10-13
DK3106149T3 (da) 2020-02-24
TWI646980B (zh) 2019-01-11
TWI546094B (zh) 2016-08-21
JP5873013B2 (ja) 2016-03-01
CN102753152A (zh) 2012-10-24
CA2763939A1 (en) 2010-12-02
RU2016117972A3 (lt) 2019-09-27
IL216468B (en) 2018-12-31
HK1247095A1 (zh) 2018-09-21
EP3106149A1 (en) 2016-12-21
US20110023876A1 (en) 2011-02-03
HUE047834T2 (hu) 2020-05-28
KR20170104003A (ko) 2017-09-13
MX2011012684A (es) 2012-05-23
HUE029532T2 (en) 2017-03-28
PL2435024T3 (pl) 2017-01-31
JP6492124B2 (ja) 2019-03-27
KR20180130602A (ko) 2018-12-07
RU2586297C2 (ru) 2016-06-10
TW201109050A (en) 2011-03-16
US20190307676A1 (en) 2019-10-10
RU2011154083A (ru) 2013-07-10
RU2015151358A3 (lt) 2019-07-29
NO2021019I1 (no) 2021-05-12
TW201936174A (zh) 2019-09-16
KR101976107B1 (ko) 2019-05-09
PT3106149T (pt) 2020-02-19
EP2435024B1 (en) 2016-07-06
BRPI1011229A2 (pt) 2016-03-15
EP2435025B1 (en) 2016-07-06
PH12017500778A1 (en) 2018-01-22
AU2010253770B9 (en) 2015-02-12
HRP20200260T1 (hr) 2020-05-29
KR20120026075A (ko) 2012-03-16
RU2713404C2 (ru) 2020-02-05
TW202114642A (zh) 2021-04-16
LT3111927T (lt) 2020-03-25
LTPA2021511I1 (lt) 2021-06-25
TWI717511B (zh) 2021-02-01
WO2010138868A2 (en) 2010-12-02
TW201808372A (zh) 2018-03-16
PT2435025T (pt) 2016-11-11
BRPI1011220B1 (pt) 2020-03-10
CN105193773B (zh) 2018-12-11
ME03631B (me) 2020-07-20
JP6876734B2 (ja) 2021-05-26
LT3111926T (lt) 2020-03-25
HUS2100018I1 (hu) 2021-06-28
US20170112759A1 (en) 2017-04-27
LT2435025T (lt) 2016-09-26
RU2011152960A (ru) 2013-07-10
HRP20161098T1 (hr) 2016-10-21
CN102596176A (zh) 2012-07-18
LTC2435024I2 (lt) 2022-06-27
MX2011012685A (es) 2012-06-12
HK1244669A1 (zh) 2018-08-17
LTPA2019014I1 (lt) 2019-07-10
IL216466A0 (en) 2012-01-31
PL2435025T3 (pl) 2017-08-31
US10716753B2 (en) 2020-07-21
SI3111926T1 (sl) 2020-07-31
TWI539979B (zh) 2016-07-01
AU2010253776B2 (en) 2015-01-22
ZA201108275B (en) 2023-04-26
HRP20161101T1 (hr) 2016-11-04
IL216467A0 (en) 2012-01-31
EP3106149B1 (en) 2019-11-20
EP2435023A2 (en) 2012-04-04
PT3111927T (pt) 2020-03-03
BRPI1011229B8 (pt) 2021-05-25
RU2016117972A (ru) 2018-10-29
CY1118030T1 (el) 2017-05-17
EP2435025A2 (en) 2012-04-04
HUE031229T2 (en) 2017-06-28
CY1122807T1 (el) 2021-05-05
KR20170070274A (ko) 2017-06-21
PL3111926T3 (pl) 2020-06-29
WO2010138862A3 (en) 2011-04-14
HUE047803T2 (hu) 2020-05-28
DK3111926T3 (da) 2020-03-02
TW201700123A (zh) 2017-01-01
US20210186861A1 (en) 2021-06-24
HRP20200298T1 (hr) 2020-06-12
CN102753152B (zh) 2015-09-23
WO2010138884A3 (en) 2011-04-21
IL216467B (en) 2018-12-31
HK1169307A1 (zh) 2013-01-25
KR20120015334A (ko) 2012-02-21
US20180125776A1 (en) 2018-05-10
DK2435025T3 (en) 2016-10-24
RU2751771C2 (ru) 2021-07-16
CN107669664B (zh) 2020-07-10
RU2580315C3 (ru) 2021-06-18
JP5823383B2 (ja) 2015-11-25
AU2010253950C1 (en) 2015-09-17
DK2435024T3 (en) 2016-10-24
DK3111927T3 (da) 2020-03-09
MX350164B (es) 2017-08-29
US9463161B2 (en) 2016-10-11
EP3111926B1 (en) 2019-12-11
CN102458364A (zh) 2012-05-16
MX350163B (es) 2017-08-29
IL216468A0 (en) 2012-01-31
JP2019108369A (ja) 2019-07-04
JP2012528200A (ja) 2012-11-12
ES2589135T3 (es) 2016-11-10
CY1122732T1 (el) 2021-03-12
CN107412212A (zh) 2017-12-01
JP6189356B2 (ja) 2017-08-30
MX2011012783A (es) 2012-06-28
LUC00124I1 (lt) 2019-06-13
PL2435023T3 (pl) 2017-06-30
ES2592536T3 (es) 2016-11-30
TWI707700B (zh) 2020-10-21
TWI632926B (zh) 2018-08-21
TWI792140B (zh) 2023-02-11
EP3111927B1 (en) 2019-12-11
SI3106149T1 (sl) 2020-07-31

Similar Documents

Publication Publication Date Title
HUS2100018I1 (hu) Hatóanyagok légúti beadására alkalmas készítmények és ezekkel kapcsolatos eljárások
EP2406379A4 (en) COMPOSITIONS AND METHODS FOR RELEASING BIOLOGICALLY ACTIVE RNA
EP2493474A4 (en) METHOD AND COMPOSITIONS FOR DELAYED ACTIVE INGREDIENT EXTRACTION
IL210185A0 (en) Methods, compositions and systems for local delivery of drugs
HK1170679A1 (en) Compositions and methods for drug delivery
IL229260A0 (en) Preparations, methods and systems for respiratory administration of two or more active agents
EP2643045A4 (en) THERAPEUTIC PROCESSES AND COMPOSITIONS FOR SOLID FORM DELIVERY
EP2635260A4 (en) COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS
EP2794879A4 (en) COMPOSITIONS AND METHODS FOR RELEASING BIOLOGICALLY ACTIVE RNA
IL225485A0 (en) System and preparations for increased transport of medicine through the cheek tissue in the oral cavity
IL222218A0 (en) System amd method for dethod for delivery of suspensions and other micropatricle compositions